Glaukos (GKOS) Stock Soars After Huge Earnings Beat

Glaukos Corporation surged as promising glaucoma treatment data and regulatory momentum lifted investor confidence; stocks have been trading up by 33.01 percent.

Live Update At 15:02:36 EDT: On Thursday, October 29, 2026 Glaukos Corporation stock [NYSE: GKOS] is trending up by 33.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

GKOS just put up the kind of quarter that gets momentum traders’ attention. Glaukos reported Q3 revenue of about $211M, far above the roughly $168M consensus. On the bottom line, adjusted EPS swung to a profit of $0.47 versus expectations around a loss near -$0.09 to -$0.10. For a name that still shows negative margins on trailing metrics, that’s a powerful near-term inflection.

The chart confirms it. Before the earnings release on 2026/10/28, GKOS had been grinding in the mid‑$160s to high‑$170s. After the report, the stock jumped to a 2026/10/28 close near $181.43, then exploded to a 2026/10/29 close around $241.33 with an intraday high of $242.40. That’s a textbook earnings breakout.

Intraday, GKOS held most of its gap, consolidating between $235 and $242 for hours. That behavior tells traders there was real demand behind the move, not just a quick squeeze. Valuation is rich — price‑to‑sales near 15.95 and price‑to‑book above 14 — but Glaukos also posts strong 60.7% gross margins and rapid revenue growth. For active traders, GKOS now trades like a high‑expectation growth leader, where surprises matter more than legacy losses.

Why Traders Are Watching GKOS Momentum

Glaukos is not just popping on a headline; it is stacking catalysts. The Q3 beat is the anchor. Revenue of about $211M versus roughly $168M and adjusted EPS of $0.47 versus a negative consensus signaled that core products like iDose TR and Epioxa are scaling faster than the Street modeled. That shock is exactly what drove GKOS roughly 14% higher after earnings and set up the follow‑through rally.

Forward guidance is the second leg of this story. Glaukos guided FY26 revenue to $775M–$785M and FY27 to $1.0B, both meaningfully ahead of current estimates around $691.7M and $852.5M. That implies Glaukos expects a steep growth ramp over the next two years, which often supports higher trading multiples when the tape is strong. For traders, GKOS now has a clear “numbers up” narrative to trade around on each quarterly update.

The clinical data is the third leg. Phase 4 topline results for the iDose TR implant used with cataract surgery showed statistically significant and clinically meaningful extra intraocular pressure reductions versus surgery alone, with all primary and key secondary endpoints met and safety in line with prior data. That de‑risks a major glaucoma franchise and backs the revenue ramp baked into guidance.

At the same time, three‑year Phase 3 extension data for Epioxa in keratoconus showed durable efficacy and clean long‑term safety after a single treatment, strengthening the corneal cross‑linking story. Add the RevOpsis license — RO‑104 and the RevMod retinal platform — and traders see Glaukos building a three‑pillar model: glaucoma, corneal disease, and retinal biologics. Analyst reactions line up with this view, with BTIG lifting its GKOS target to $205 and Mizuho boosting to $190, both reinforcing bullish sentiment despite broader MedTech volume worries.

Conclusion

For active traders, GKOS has flipped from a “promising story” to a live momentum play backed by real numbers. Glaukos delivered a massive positive earnings surprise, showed operating leverage in the quarter, and then raised the bar with FY26 and FY27 revenue targets far above the Street. The stock’s surge from the $170s to the $240s in two days reflects traders repricing that new growth trajectory.

Under the hood, the puzzle pieces fit together. iDose TR Phase 4 data supports wider adoption in glaucoma tied to cataract surgery. Epioxa’s three‑year durability points to a sticky corneal revenue stream. The RevOpsis deal pushes Glaukos into retinal diseases with a tri‑specific biologic and a discovery platform that add longer‑term upside optionality. All of that feeds into the multi‑year guidance Glaukos just issued.

For the Tim Sykes crowd, this is the kind of setup that demands discipline. As Tim often says, “I trade the news, but I always respect the risk and cut losses quickly.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. GKOS has news, volume, and a powerful chart, but it also has a rich valuation and high expectations. This article is for educational and research purposes only — not a signal to buy or sell — but GKOS now sits firmly on the radar of traders who study earnings breakouts, watch guidance, and let price action confirm the story.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks